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Abstract
We report a case of near fatal aortic thrombosis in a trauma patient homozygous for mutation of Factor V Leiden.
He responded well to vascular surgery and intensive care unit management and was discharged successfully from
the hospital one month later.
Background
Thrombophilia may be described as a congenital or an
acquired tendency to arterial and venous thrombosis.
Mutation of Factor V Leiden (FVL) appears as a major
predisposing factor for venous thromboembolism and
has a high prevalence in the Caucasian population [1].
The relative risk (RR) for the first incident of venous
thrombosis and the annual incidence (AI) values asso-
ciated with this mutation are 7.0 and 0.06%, respectively,
in heterozygotes. For homozygotes, RR and AI values
are projected to be as high as 80 and 0.5-1.0%, respec-
tively [2,3].
The lifetime probability of developing thrombosis is
2.2 for carriers of the FVL mutation, which is quite low
compared to carriers of antithrombin deficiency (8.1),
protein S deficiency (8.5) and protein C deficiency (7.3)
[4]. There is still debate regarding the utility of lifetime
anticoagulation in patientsw i t hF V L ,w i t ho n es t u d y
randomizing patients on warfarin versus placebo show-
ing a risk value reduction in recurrent venous throm-
boembolism of 76-80% in the warfarin group. According
to the investigators, anticoagulation therapy should
exceed a 3-month period after the first venous throm-
boembolic episode with conventional international nor-
malized ratio (INR) target between 2 and 3 [5,6].
Carriage of FVL mutation is highly linked to venous but
not arterial thrombosis; however, there is growing evi-
dence linking this mutation to an increased risk for
arterial involvement, specifically for myocardial infarc-
tion [7-9]. We herein present a rare case of aortic
thrombosis in a trauma patient that was found to be
homozygous for FVL mutation.
Case presentation
A 32-year-old male, presented to the ER of an outside
hospital complaining about numbness in both legs after
being involved in a street fight 3 days ago. He was a
non-smoker with non-significant previous medical his-
tory. Physical examination was unrevealing and vital
signs were normal. Radiologic evaluation revealed only a
fracture of the 10
th left rib and the patient was dis-
charged with instructions for bed rest.
In the next 24 hours he gradually developed abdom-
inal pain and complained about excessively numb and
cold legs with normal urination and defecation. By the
time he presented to the ER of the same hospital, he
could not move his legs. On physical examination, there
were no palpable pulses in all arterial sites of both lower
extremities. An emergent CT angiography was per-
formed revealing a large (5.8 cm length and 0.8 cm
width) thrombus in the descending aorta, causing partial
occlusion of its lumen (Figure 1), as well as an infra-
renal thrombus extending into both iliac branches, caus-
ing complete lumen occlusion. He was started on intra-
venous drip of unfractionated heparin, clopidogrel and
warfarin and a few hours later he was transferred to our
department for further management.
A successful surgical recanalization was immediately
performed by the vascular surgeons and postoperatively
the patient was transferred intubated to our intensive
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with a peak creatine kinase (CK) and myoglobin levels
of 130,000 U/L (with CK-MB value of 15,000 U/L) and
3,000, respectively. The LDH level was 6,545 U/L and
liver function tests revealed AST and ALT levels of
1,297 and 340 U/L, respectively. He also developed
acute renal failure (ARF), hyperkalemia and severe tibial
compartment syndrome of the left leg necessitating
fasciotomies.
Taking into account the patient’s young age, compli-
cated clinical course and laboratory hypercoagulative
profile (PLTs were 625,000/ml and fibrinogen was 663
mg/dL), as well as the fact that he had no other clinical
or imaging evidence of venous thrombosis, we decided
to perform a thrombophilia work-up. The rapid and
life-threatening course of the disease had understandably
forced the referring physicians from the outside hospital
to initiate aggressive anticoagulation therapy. This did
not allow us to perform antithrombin III, protein C and
S testing. However, the patient was found to carry a
homozygous mutation for FVL and also heterozygous
mutations for Factor XIII and beta-FIBR. Of interest, his
family history was non-significant for thromboses.
When renal function improved, we switched from
unfractionated heparin to low-molecular weight heparin
and administered warfarin aiming at a therapeutic target
INR between 2 and 3.
During the rest of his ICU hospitalization he remained
hemodynamically stable, his ARF responded well to con-
tinuous veno-venous hemodiafiltration and was finally
extubated on day 15. The patient was transferred to the
Vascular Surgery Department for further management
and discharged from the hospital a month later.
Discussion
Cases of heterozygous FVL mutation causing arterial
disease are rare and have been described mostly in neo-
nates [10-12]. Other cases of aortic arch and peripheral
arterial thrombosis have also been reported in adults
[13,14]. The synergistic effects of FVL mutation and
other prothrombotic conditions such as homocystine-
mia, protein C and S deficiency, oral contraceptives and
pregnancy have been also previously described [15].
There are cases of post-traumatic arterial thrombosis
of several vascular sites (femoral, renal, cranial, abdom-
inal), not necessarily associated with prothrombotic
conditions [16-18]. The incidence of abdominal aortic
trauma resulting from blunt force is only around 5%
Figure 1 CT images demonstrating the occlusive thrombus in the descending thoracic aorta (black arrows).
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abdominal aorta [19].
A Medline search triggered by the current case report
(literature review performed on April 2, 2011) and using
the search terms “abdominal aortic thrombosis“ AND
“trauma“ revealed 15 case reports and 2 case series.
Thrombotic episodes were mainly associated with major
blunt trauma in automobile accidents (predominantly
during childhood), with no clear predisposing thrombo-
tic factors. The low reported number of similar cases
does not allow us to safely determine whether the find-
ing of a hypercoagulable genetic profile in a trauma
patient experiencing a thrombotic episode is causally
linked or merely co-incidental. However, we support the
notion that a thrombophilia work-up might be a pru-
dent choice when extensive thromboses are observed in
young trauma patients suffering low-impact traumatic
injuries.
Conclusions
Homozygous mutation of FVL as well as the arterial
site of the first thrombotic event are rare incidents.
Although arterial thrombosis occurs commonly on sites
of previous vascular pathology (i.e. an atherosclerotic
plaque), recent clinical evidence suggests that in cases of
extensive arterial thrombosis, a thrombophilia work-up
may be required. Aggressive surgical management may
be needed if the arterial incident is severe while the life-
time use of warfarin prophylaxis is still debated.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Author details
12
nd Critical Care Department, Athens University School of Medicine -
“Attiko” University Hospital, 1 Rimini Str., Haidari - Athens, 12462, Greece.
2Laboratory of Hematology & Blood Bank Unit, Athens University School of
Medicine - “Attiko” University Hospital, 1 Rimini Str., Haidari - Athens, 12462,
Greece.
Authors’ contributions
TI and PK participated in patient management and data collection, TG
participated in patient management, data collection and drafted the
manuscript, TA carried out the thrombophilia work-up and AA participated
in patient management, supervised and approved the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 February 2011 Accepted: 9 May 2011
Published: 9 May 2011
References
1. Franchini M, Lippi G: Factor V Leiden and hemophilia. Thromb Res 2010,
125:119-123.
2. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM:
Venous thrombosis due to poor anticoagulant response to activated
protein C: Leiden Thrombophilia Study. Lancet 1993, 342:1503-1506.
3. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of
thrombosis in patients homozygous for factor V Leiden (activated
protein C resistance). Blood 1995, 85:1504-1508.
4. Martinelli I, Mannucci PM, De Stefano V, et al: Different risks of thrombosis
in four coagulation defects associated with inherited thrombophilia: a
study of 150 families. Blood 1998, 92:2353-2358.
5. Sarasin FP, Bounameaux H: Decision analysis model of prolonged oral
anticoagulant treatment in factor V Leiden carriers with first episode of
deep vein thrombosis. BMJ 1998, 316:95-99.
6. Ridker PM, Goldhaber SZ, Danielson E, et al: Long-term, low-intensity
warfarin therapy for the prevention of recurrent venous
thromboembolism. N Engl J Med 2003, 348:1425-1434.
7. Dorweiler B, Neufang A, Kasper-Koenig W, Schinzel H, Schmiedt W,
Oelert H: Arterial embolism to the upper extremity in a patient with
factor V Leiden mutation (APC resistance)–a case report and review of
the literature. Angiology 2003, 54:125-130.
8. Middendorf K, Gohring P, Huehns TY, Seidel D, Steinbeck G, Nikol S:
Prevalence of resistance against activated protein C resulting from
factor V Leiden is significantly increased in myocardial infarction:
investigation of 507 patients with myocardial infarction. Am Heart J 2004,
147:897-904.
9. Mansourati J, Da Costa A, Munier S, et al: Prevalence of factor V Leiden in
patients with myocardial infarction and normal coronary angiography.
Thromb Haemost 2000, 83:822-825.
10. Patel RK, Ingram W, MacCarthy P, Arya R: Is homozygosity for factor V
Leiden a risk factor for myocardial infarction in young women who
smoke? Thromb Haemost 2005, 93:616-661.
11. Doix S, Mahrousseh M, Jolak M, Laurent Y, Lorenzini JL, Binquet C, Zeller M,
Cottin Y, Wolf JE: Factor V Leiden and myocardial infarction: a case,
review of the literature with a meta-analysis. Ann Cardiol Angeiol (Paris)
2003, 52:143-149.
12. Metsvaht T, Hermlin T, Kern H, Kahre T, Starkopf J: Aortic arch thrombosis
in a neonate with heterozygous carrier status of factor V Leiden
mutation. Congenit Heart Dis 2006, 1:40-45.
13. Ng T, Brown JR, Edmondson RA, Tillyer ML: Catastrophic arterial
thromboembolism associated with factor V Leiden. Eur J Vasc Endovasc
Surg 2000, 19:551-553.
14. Mandegar MH, Saidi B, Roshanali F: Extensive arterial thrombosis in a
patient with factor V Leiden mutation. Interact Cardiovasc Thorac Surg
2010, 11:127-129.
15. Page C, Rubin LE, Gusberg RJ, Dardik A: Arterial thrombosis associated
with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and
peripheral arterial disease: importance of synergistic factors. J Vasc Surg
2005, 42:1014-1018.
16. Bahloul M, Abid D, Ketata H, Kallel H, Dammak H, Chelly H, Ben Hamida C,
Mhiri MN, Bouaziz M: Traumatic unilateral renal artery thrombosis and
protein C deficiency. A case report. J Mal Vasc 2006, 31:277-279.
17. Leo LA, Grigoratos C, Spontoni P, Violo C, Balbarini A: An unusual case of
traumatic occlusion of the left common femoral artery: a case report.
J Cardiovasc Med (Hagerstown) 2010.
18. Kim C, Jeon W, Shin T, Choi D, Kim J, Lee C, Choi J: Stent-assisted
recanalisation of acute occlusive arteries in patients with acute limb
ischaemia. Eur J Vasc Endovasc Surg 2010, 39:89-96.
19. Kepros J, Angood P, Jaffe CC, Rabinovici R: Aortic intimal injuries from
blunt trauma: resolution profile in nonoperative management. J Trauma
2002, 52:475-78.
doi:10.1186/1477-9560-9-8
Cite this article as: Tsangaris et al.: Life-threatening aortic thrombosis in
a trauma patient homozygous for factor V Leiden mutation: Case
report. Thrombosis Journal 2011 9:8.
Tsangaris et al. Thrombosis Journal 2011, 9:8
http://www.thrombosisjournal.com/content/9/1/8
Page 3 of 3